Effects of Losartan and Delapril on the Fibrinolytic System in Patients with Mild to Moderate Hypertension

Clinical Drug Investigation

Volumn 23, Issue 11, 2003, Pages 717-724

  Paterna, Salvatore ^a   Di Garbo, Vincenzo ^b   Avellone, Gino ^b   Di Pasquale, Pietro ^c   Cacia, Antonina ^c   Tuttolomondo, Antonio ^b   Follone, Giuseppe ^b   Cardinale, Antonietta ^a   Maniscalchi, Tiziana ^a   Licata, Giuseppe ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Ospedale GF Ingrassia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0242593956     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323110-00004     Document Type: Article

References (39)

1. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-32
2. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement (SAVE) trial. SAVE investigators. N Engl J Med 1992; 327: 669-77
4. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22
5. Fourth International Study of Infarct Survival Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in over 58050 patients with suspected acute myocardial infarction: ISIS-4. Lancet 1995; 345: 669-85
6. Loshkutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115
7. Robbie LA, Bennet AM, Croll AM, et al. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 127-33
8. Lucore CL, Sobel B. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988; 77: 660-9
9. Farrehi PM, Ozaki Ck, Carmeliet P, et al. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97: 1002-8
10. Braaten JV, Handt S, Jerome WG. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor-1. Blood 1993; 81: 1290-9
11. Vassalli JD, Sappino A, Belin D. The plasminogen activator plasmin system. J Clin Invest 1991; 88: 1067-72
12. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation 1993; 88: 2030-4
13. De Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator mass concentration on long-term mortality in patients at risk from ischaemic heart disease. Br Heart J 1994; 71: 504-7
14. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet 1997; 349: 747-52
15. Goodfield NE, Newby DE, Ludlam CA, et al. Effects of acute angiotensin II type1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-5
16. Erdem Y, Usalan C, Haznedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12 (11): 1071-6
17. Labinsky C, Newby DE, Pellegrini MP, et al. Potentiation of bradykinin induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 2001; 38: 1402-8
18. Newby DE, Wright RA, Ludlam C, et al. An in vivo model for the assessment of the acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997; 78: 1242-8
19. Wright RA, Flapen AD, Alberti KG, et al. Effect of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73
20. Vaughan DE, Roleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: Heart Study Investigators. Circulation 1997; 96: 442-7
21. Oshima S, Ogawa H, Mizumo Y, et al. Effect of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 1997; 134: 961-6
22. Ridker PM, Gaboury CL, Conlin PR. et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-73
23. Wright RA, Flapan AD, Alberti KGMM, et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73
24. Van Leeuwen RTJ, Kol A, Andreotti F. Angiotensin II increases plasminogen inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-8
25. Nakamura S, Nakamura I, Ma L, et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 460-1
26. Kawano H, Do SY, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101: 1130-7
27. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-6
28. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419-29
29. Witherow FN, Dawson P, Ludlam CA, et al. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol 2002; 40: 961-6
30. Pretorius M, Rosenbaum D, Vaughan DF, et al. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003; 107: 579-85
31. Moriguchi A, Brosnihan KB, Kumagai H, et al. Mechanisms of hypertension in transgenic rats expressing the mouse ren-2 gene. Am J Physiol 1994 Apr; 266 (4 Pt 2): R1273-9
32. Abrahamsen CT, Pullen MA, Schnackenburg CG, et al. Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat. Pharmacology 2002; 66 (1): 26-30
33. Kerins DM, Hoo Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96 (5): 2515-20
34. Mehta JL, Li DJ, Yang H, et al. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J Cardiovasc Pharmacol 2002; 39 (6): 789-94
35. Schmaier AH. The kallikrein-kinin and the rennin angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1-13
36. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285-90
37. Katoh M, Egashira K, Mitsui T, et al. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol 2000; 35: 932-6
38. Chen HC, Bouchie JL, Perez AS, et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vase Biol 2000; 20: 2297-30
39. Sironi L, Calvio AM, Arnalboldi L, et al. Effect of valsartan on angiotensin-II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 2001; 37: 961-6